<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084599</url>
  </required_header>
  <id_info>
    <org_study_id>have net been approved</org_study_id>
    <nct_id>NCT05084599</nct_id>
  </id_info>
  <brief_title>Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section</brief_title>
  <official_title>Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section：A Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For hypotension after spinal anesthesia, metaraminol has different 90% effective doses in the&#xD;
      supine position and the left-tilt position. We plan to conduct a non-inferiority trial to&#xD;
      compare the effects of the two on the fetus and the mother.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Umbilical artery blood pH</measure>
    <time_frame>30 seconds after delivery</time_frame>
    <description>pH value of fetal umbilical artery blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypotension</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Number of Participants with systolic blood pressure reduction &gt;20% baseline value or systolic blood pressure &lt;90 mm Hg before delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bradycardia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Number of Participants with heart rate was ≤50 bpm before delivery Number of Participants with heart rate was ≤50 bpm before delivery Number of Participants with heart rate was ≤50 bpm before delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of nausea in pregnant women</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Anesthesiologist observes combined patient dictation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical artery blood base excess</measure>
    <time_frame>30sec after delivery</time_frame>
    <description>base excess of fetal umbilical artery blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of vomiting in pregnant women</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Anesthesiologist observes combined patient dictation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>left-tilt group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After spinal anesthesia, the patient was placed in a 15° left position until the fetus was delivered, and metaraminol was given at an initial rate of 2.00μg/kg/min throughout the process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaraminol 2.7μg/kg/min</intervention_name>
    <description>After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.</description>
    <arm_group_label>supine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaraminol 2μg/kg/min</intervention_name>
    <description>After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.</description>
    <arm_group_label>left-tilt group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Singleton pregnancy at term scheduled to be delivered via elective cesarean delivery;&#xD;
&#xD;
          2. height 150-180 cm;&#xD;
&#xD;
          3. American Society of Anesthesiologists (ASA) physical status II-III;&#xD;
&#xD;
          4. body mass index (BMI) &lt;35 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. transverse presentation, fetal macrosomia;&#xD;
&#xD;
          2. uterine abnormalities (eg, large fibroids, bicornuate uterus);&#xD;
&#xD;
          3. polyhydramnios;&#xD;
&#xD;
          4. ruptured membranes, oligohydramnios;&#xD;
&#xD;
          5. intrauterine growth restriction;&#xD;
&#xD;
          6. gestational or nongestational hypertension, diabetes, or eclampsia;&#xD;
&#xD;
          7. hypertensive disorders or any condition associated with autonomic neuropathy (such as&#xD;
             diabetes mellitus for &gt;10 years) or renal failure;&#xD;
&#xD;
          8. contraindications for combined spinal-epidural anesthesia;&#xD;
&#xD;
          9. participants who declined to sign informed consent forms.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Yi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Yi</last_name>
    <phone>+8613601083503</phone>
    <email>yifeng65@sina.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yi Feng, MD</investigator_full_name>
    <investigator_title>Head of Anesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metaraminol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

